Diabetic Med:评估葡萄糖水平的即时测量与参考实验室测试的效用

2019-05-08 不详 网络

近日,国际杂志 《Diabetic Med》上在线发表一项关于评估葡萄糖水平的即时测量与参考实验室测试的效用的研究。 在定义血糖状态时评估即时测量和实验室参考葡萄糖值之间的一致性水平。 研究人员在圣胡安超重成人纵向研究中分析了年龄40-65岁1292名超重/肥胖的非机构化参与者。使用即时Bayer Contour血糖仪和Vitros System 250仪器(实验室)测定空腹静脉血糖

近日,国际杂志 《Diabetic Med》上在线发表一项关于评估葡萄糖水平的即时测量与参考实验室测试的效用的研究。

在定义血糖状态时评估即时测量和实验室参考葡萄糖值之间的一致性水平。

研究人员在圣胡安超重成人纵向研究中分析了年龄40-651292名超重/肥胖的非机构化参与者。使用即时Bayer Contour血糖仪和Vitros System 250仪器(实验室)测定空腹静脉血糖。美国糖尿病协会的阈值用于将参与者分为正常血糖(<5.6 mmol / l),前驱糖尿病5.66.9 mmol / l)或糖尿病组(≥7mmol / l)。

Bland-Altman图分析显示,两种方法的平均差异和平均值之间的回归的斜率为0.04P = 0.002)。正常血糖(β= -0.57P <0.001)和前驱糖尿病(β= -0.75P <0.001)之间的斜率与零显著不同,但糖尿病患者中没有(β= -0.02P = 0.68)。当前驱糖尿病和糖尿病组合并为一组时,斜率为0.01,并且使用这两种方法葡萄糖值保持相似(P = 0.76)。

即时血糖测量可用于筛查患有糖尿病的人,并且可以评估糖尿病患者血液中的葡萄糖,但实验室测试不可用或不合时宜。

原始出处:

O. M. AndriankajaF. J. MuñozTorresJ. L. Vergaraet al. Utility of pointofcare vs reference laboratory testing for the evaluation of glucose levels

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639123, encodeId=e68e1639123ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 21 22:31:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761130, encodeId=9fd21e611303d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Mar 04 13:31:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970737, encodeId=32fa19e07379a, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 22 07:31:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609759, encodeId=e6a21609e5961, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 10 03:31:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639123, encodeId=e68e1639123ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 21 22:31:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761130, encodeId=9fd21e611303d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Mar 04 13:31:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970737, encodeId=32fa19e07379a, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 22 07:31:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609759, encodeId=e6a21609e5961, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 10 03:31:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639123, encodeId=e68e1639123ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 21 22:31:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761130, encodeId=9fd21e611303d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Mar 04 13:31:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970737, encodeId=32fa19e07379a, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 22 07:31:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609759, encodeId=e6a21609e5961, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 10 03:31:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639123, encodeId=e68e1639123ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 21 22:31:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761130, encodeId=9fd21e611303d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Mar 04 13:31:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970737, encodeId=32fa19e07379a, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 22 07:31:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609759, encodeId=e6a21609e5961, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 10 03:31:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]

相关资讯

Pediatrics:美国儿科学会发布指南,对于28天至18岁患者,输液应使用氯化钾葡萄糖等渗溶液

近期,美国儿科学会发布新的临床实践指南,建议大多数28天至18岁需要维持性静脉输液的患者,使用含有适当氯化钾和葡萄糖的等渗溶液。

Stroke:葡萄糖改变急性卒中患者血管内血栓切除术的效果

由此可见,与标准治疗相比,EVT改善了卒中预后,无论血糖水平如何,但在较低葡萄糖水平下治疗效果较大,显著的相互作用持续高达90至100mg/dL(5.0-5.5 mmol/L)。在大血管卒中后严格控制葡萄糖是否能提高EVT的疗效需要进行适当的检测。

常熟一医院回应“给患者输注过期葡萄糖”:偶然事件,将追责

针对有患者家属反映,江苏常熟市第一人民医院向患者输注了过期5个月之久的乐加(钠钾镁钙葡萄糖注射液)之事,5月5日,涉事医院副院长叶宏伟向记者回应,经调查认定,该患者输注的乐加注射液确系过期。医院将会在调查清楚根本原因后,对相关人员进行追责处理。“这确实是我们工作中的疏漏,再次向患者及家属表达诚恳的歉意。”常熟市第一人民医院法人代表陈波5日晚间对澎湃新闻表示,会严肃处理此事。叶宏伟称,5月1日中午,

Cell Metab:糖真的有毒!高血糖环境下,胰腺细胞中致癌的KRAS突变暴增,或为导致胰腺癌的罪魁祸首之一

近日,中国台湾中央研究院的胡春美和李文华等研究发现,胰腺癌中极为常见的KRAS突变,竟与高血糖关系密切!高血糖引起的一系列代谢变化,让胰腺细胞缺乏合成修复DNA的原料dNTP,KRAS突变频率翻着倍的往上长。相关研究发表在Cell Metabolism上。

PLOS ONE:重症监护病房患者谵妄期间的葡萄糖变异性:一项前瞻性队列研究

最近,研究人员进行了一项前瞻性队列研究,来探究在重症监护病房(ICU)中,糖尿病和非糖尿病的重症患者谵妄期间葡萄糖变异性与非谵妄期间相比是否有所改变。

Diabetic Med:地塞米松预防妇科肿瘤化疗后间质葡萄糖的日间变化

近日,国际杂志 《Diabetic Med》上在线发表一项关于地塞米松预防妇科肿瘤化疗后间质葡萄糖的日间变化的研究。 高血糖是急性糖皮质激素暴露的副作用之一,且与接受化疗的患者预后不良有关。在化学治疗的背景下糖皮质激素诱导的葡萄糖失调的发生率,危险因素和昼夜分布仍未完全了解。 在卡铂/紫杉醇化疗联合地塞米松治疗妇科癌症之前和之后5天,对16名无糖尿病的女性进行盲法连续血糖监测24小时